



**3<sup>rd</sup> POSTGRADUATE**  
**Lymphoma**  
**Conference**

Rome,  
March 23-24  
2017

**VOI Donna Camilla Savelli Hotel**

**Presidents:**

A.M. Carella  
P.L. Zinzani

**Scientific Committee:**

A.M. Carella  
B.D. Cheson  
S.A. Pileri  
A. Younes  
P.L. Zinzani

3<sup>rd</sup> POSTGRADUATE  
**Lymphoma  
Conference**

Rome,  
March 23-24  
2017

**Faculty**

Ranjana	<b>Advani</b>	Stanford, USA
Stephen M.	<b>Ansell</b>	Rochester, USA
Christian	<b>Buske</b>	Ulm, Germany
Angelo Michele	<b>Carella</b>	Genoa, Italy
Jorge J.	<b>Castillo</b>	Boston, USA
Robert	<b>Chen</b>	Duarte, USA
Selina	<b>Chen-Kiang</b>	New York, USA
Bruce D.	<b>Cheson</b>	Washington, USA
Andrew	<b>Davies</b>	Southampton, United Kingdom
Martin	<b>Dreyling</b>	Munich, Germany
John F.	<b>Gerecitano</b>	New York, USA
Olivier	<b>Hermine</b>	Paris, France
Georg	<b>Hess</b>	Mainz, Germany
Wojciech	<b>Jurczak</b>	Kraków, Poland
Steven	<b>Le Gouill</b>	Nantes, France
Brian	<b>Link</b>	Iowa City, USA
Peter	<b>Martin</b>	New York, USA
Ari M.	<b>Melnick</b>	New York, USA
Craig H.	<b>Moskowitz</b>	New York, USA
Owen A.	<b>O'Connor</b>	New York, USA
Stefano A.	<b>Pileri</b>	Milan, Italy
Simon	<b>Rule</b>	Plymouth, United Kingdom
Alexandra	<b>Traverse-Glehen</b>	Lyon, France
Wyndham H.	<b>Wilson</b>	Bethesda, USA
Anas	<b>Younes</b>	New York, USA
Pier Luigi	<b>Zinzani</b>	Bologna, Italy

Thursday, March 23, 2017

8.30 am Welcome and Introduction  
*A.M. Carella, P.L. Zinzani*

## Session I

### **Mantle Cell Lymphoma**

*Chairmen: M. Dreyling, P. Martin*

8.45 am **New research issues**  
*S. Chen-Kiang*

9.00 am General discussion

9.15 am **Front-line treatment in young patients:**  
• **European perspective** *M. Dreyling*  
• **American perspective** *P. Martin*  
• **Role of maintenance therapy** *S. Le Gouill*

10.00 am General discussion

10.15 am **Round Table - Relapsed/refractory setting:**  
• **Lenalidomide** *P. Martin*  
• **Temsirolimus** *G. Hess*  
• **Bortezomib** *O.A. O'Connor*  
• **Ibrutinib** *M. Dreyling*  
• **Allotransplant** *O. Hermine*

11.30 am General discussion

11.45 am Coffee break

12.00 pm **Newer agents:**  
• **Acalabrutinib** *S. Rule*  
• **Venetoclax** *S. Le Gouill*  
• **Palbociclib** *P. Martin*  
• **BGB-3111** *S. Rule*

1.00 pm General discussion

1.15 pm Lunch

Mantle Cell Lymphoma

Mantle Cell Lymphoma

## Session II

### **Hodgkin Lymphoma**

*Chairman: A. Younes*

#### **Relapsed/refractory setting:**

2.30 pm **Brentuximab Vedotin**  
*A. Younes*

2.45 pm General discussion

3.00 pm **Nivolumab**  
*S.M. Ansell*

3.15 pm General discussion

3.30 pm **Pembrolizumab**  
*R. Chen*

3.45 pm General discussion

4.00 pm **Response criteria on checkpoint inhibitors treatment**  
*B.D. Cheson*

4.15 pm General discussion

4.30 pm **Autotransplant and beyond**  
*C.H. Moskowitz*

4.45 pm General discussion

5.00 pm **Issues for the Round Table - all speakers:**  
• **Treatment choice for CRs during checkpoint inhibitors**  
• **Checkpoint inhibitors post allotransplant**  
• **Brentuximab Vedotin and checkpoint inhibitors in front-line setting**

5.45 pm General discussion

Hodgkin Lymphoma

Hodgkin Lymphoma

Friday, March 24, 2017

8.00 am LECTURE  
**News on T-cell lymphoma drugs**  
*R. Advani*

8.20 am General discussion

### Session III

## **Follicular Lymphoma**

*Chairman: B.D. Cheson*

8.30 am **WHO news**  
*S.A. Pileri*

8.45 am General discussion

9.00 am **Epigenetic news in follicular lymphoma**  
*A.M. Melnick*

9.15 am General discussion

9.30 am **Transformed follicular lymphoma:  
biology and treatment**  
*B.L. Link*

9.45 am General discussion

10.00 am **New biological agents (single agent and combo):**  
• **PI3K inhibitors** *A. Younes*  
• **BTK inhibitors** *B.D. Cheson*  
• **BCL-2 inhibitors** *J. Gerecitano*

10.45 am General discussion

11.00 am **New anti-CD20 monoclonal antibodies**  
*C. Buske*

11.15 am General discussion

11.30 am **Biosimilar rituximab**  
*W. Jurczak*

11.45 am General discussion

12.00 pm Lunch

## Follicular Lymphoma

Follicular Lymphoma

### Session IV

## **Diffuse Large B-Cell Lymphoma**

*Chairman: A.M. Carella*

1.00 pm **Debate - Primary mediastinal lymphoma:**  
• **R-DA-EPOCH** *W. Wilson*  
• **I-II-III generation chemotherapy regimens** *A. Davies*

1.30 pm General discussion

1.45 pm **Double-hit and double-protein-expression lymphomas:  
aggressive and refractory lymphomas:**  
• **Molecular data** *A. Traverse-Glehen*  
• **Clinical presentation** *B.L. Link*

2.15 pm General discussion

2.30 pm **Plasmoblastic lymphoma**  
*J.J. Castillo*

2.45 pm General discussion

3.00 pm **New agents**  
*S.M. Ansell*

3.15 pm General discussion

3.30 pm Arrivederci  
*A.M. Carella, P.L. Zinzani*

## Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

With an unrestricted educational grant of:



abbvie



SANDOZ A Novartis Division



## GENERAL INFORMATION

### Meeting Venue

VOI Donna Camilla Savelli Hotel  
Via Garibaldi, 27  
00153 Rome, Italy  
Phone: +39 06 588861  
[www.hoteldonnacamillasavelli.com](http://www.hoteldonnacamillasavelli.com)

### Official Language

English.

### Slides

Slides must be in English. Computer videoprojection will be available in Power Point. Other requirements should be communicated to the Organizing Secretariat as soon as possible.

Slides should be handed to the slide center one hour before the beginning of the session and collected at the end.

### Badge

All registered participants and speakers will be given a badge which they must wear to be admitted to the scientific sessions.

### Attendance certificate

A certificate will be given to all participants at the end of the meeting.

### CME

An application for Italian CME credits have been made as follows:

- Provider Studio ER Congressi SRL: ID 828-179310
- No. 15,1 CME credits for physicians (disciplines: Hematology, Oncology, Radiotherapy).
- Educational objective: "guidelines-protocols-procedures".

### Changes

Parts of the program may be changed without notice.

### Organizing Secretariat

Studio E.R. Congressi  
Via Marconi, 36 - 40122 Bologna  
Phone: +39 051 4210559 - Fax: +39 051 4210174  
E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)  
[www.ercongressi.it](http://www.ercongressi.it)